The FDA granted approval for the use of GlaxoSmithKline's Boostrix -- a vaccine against tetanus, diphtheria and whooping cough -- in adults ages 19 to 64. The decision expands GSK's market for the vaccine, which is cleared as a booster for patients ages 10 to 18.

Full Story:

Related Summaries